Oxford University’s COVID-19 vaccine has passed another test this week, with trials showing the injection led to the making of antibodies and T-cells that can fight coronavirus. We had the inside running on this. Professor Adrian Hill, who is the director of the Jenner Institute which developed the vaccine spoke at our Fiduciary Investors Global Symposium last month. You can watch the video recording of his description of the vaccine process, and his positive outlook on the results here.

 

 

Adrian Hill, Professor of Human Genetics and director of the Jenner Institute Jenner the largest university based vaccine institute in the world, was positive about the development of a vaccine.

“This looks to me as if this is very doable,” he told delegates in June. “It doesn’t mean we will be successful first time. It might take a combinate of two vaccines or multiple doses. But all that has been assessed very rapidly around the world.

“Looking at the overall picture it would be surprising if by the end of the year there wasn’t pretty good evidence that one or more vaccines were working. This looks like a do-able vaccine.”

“This is a good news message, this is doable and looks like some time later this year, ideally September there will be evidence the vaccine works,” he said. “What is quite extraordinary here, and I’ve never seen anything like it is the willingness of funders, and governments and companies to invest money at risk.”

AstraZenaca, which is manufacturing the Oxford-developed vaccine, is aiming to make two billion doses, to do that it has to start before the vaccine has been shown to work.

“There is a lot of money spent at risk, that’s good because it will save much more than that in economic benefit if we can shave a month or two or three off the deployment time. It’s worth pointing out that is an extraordinary vote of confidence in vaccine technology by well-informed agencies.”

“If ours works, several other will as well,” he said adding that the process isn’t competitive. The number of people to vaccinate means no one company has ever made a vaccine on this scale before.

Conceivably there are billions of people to vaccinate, but Hill pointed out that no one has ever made a vaccine beyond a 500 million scale. There are currently 150 vaccines in development with 12 already in the clinic, and all of them are philanthropic.

“We are trying to develop a vaccine for two billion people with AstraZeneca. This is a huge challenge for them and will manufacturing in seven countries and needs to be quick. It will need an unprecedented effort to do what we are aiming for.”

 

The Fiduciary Investors Symposium Digital looked at the extreme uncertainty of the global economy including the changing geopolitical dynamics and the potential unravelling of globalisation; the unprecedented fiscal and monetary policy responses and the implications for investments; how investors are positioning portfolios and managing short and long term risks; supply chain risks and responsible capitalism; and what a sustainable recovery looks like and how investors can ensure it happens. It brought together more than 300 institutional investors from around the world. Other speakers included Larry Summers, Stephen Kotkin and Esther Duflo. Click here for more video recordings of the sessions.

White is responsible for the content across all Conexus Financial’s institutional media and events. In addition to being the editor of top1000funds.com, she is responsible for directing the bi-annual Fiduciary Investors Symposium.
Leave a comment